Exploratory analysis of the FIGARO-DKD study with finerenone, a non-steroidal, selective mineralocorticoid receptor antagonist, indicated a reduction in renal outcomes in patients with chronic kidney…
Statistically significant and clinically important reductions in proteinuria were achieved for the primary endpoint for patients with C3G1 Additionally, statistically significant reduction in C3 protein…
Merck known as MSD outside the United States and Canada, moment blazoned that it has withdrawn its Premerger Announcement and Report Form under the Hart-Scott-Rodino…
Today, overall survival ( Zilches) data from Eli Lilly and Company’s (NYSE LLY) Verzenio ® (abemaciclib) Phase 3 monarchE study were published in a Letter…
ViiV Healthcare presents positive interim data showing Vocabria (cabotegravir) and Rekambys (rilpivirine) can be enforced successfully in a variety of European healthcare settings ViiV Healthcare,…
Takeda Pharmaceutical Company Limited (TSE:4502/NYSE:TAK) (“Takeda”) announced that its Board of Directors resolved today to engage in the acquisition of its own shares pursuant to the provision…
New analysis from the Phase III FIGARO-DKD study will be presented, which investigated the impact of finerenone on renal outcomes in patients with chronic kidney…
FIRST-EVER GENERIC COMPANY SUSTAINABILITY-LINKED NOTES Company will Increase Access to Medicines in Middle and Low Income Countries Enhanced Commitment to the Environment Teva Pharmaceutical Industries…
Small molecule candidate Anle138b targets disease modification for multiple system atrophy and other neurological disorders Teva Pharmaceutical Industries Ltd. (NYSE and TASE: TEVA) and MODAG…
Filings supported by pivotal ELARA trial, where treatment with Kymriah showed robust response rates and remarkable safety profile in adult patients with relapsed or refractory…
€5.1 million expansion will bring high quality seeds to worldwide markets faster, providing solutions for growers and meeting consumer demands / The seven-hectare global Product…
Q3 net sales grew +5% (cc¹, +6% USD) Innovative Medicines grew +7% (cc, +8% USD) Strong performance of key growth drivers: Entresto (+44% cc), Cosentyx (+22% cc), Kesimpta (USD 109 million), Jakavi (+26%…